Abstract:Abstract Background N-terminal pro-B-type natriuretic peptide (NT-proBNP) may provide incremental prognostic value in valvular heart disease (VHD). We aimed to elaborate its value in elder VHD patients and relationship with ventricular function and prognosis. Methods From China elDerly Valvular heart Disease (China-DVD) cohort study, elder VHD patients (age ≥60 years) with concomitant echocardiography and NT-proBNP measurements at baseline were included. Patients were followed every six months. The primary endpoint was 1-year all-cause mortality regardless of valvular intervention. Results In total, 6025 patients were included in the study (mean age of 71.08±7.61 years, 52.6% male, 78.6% NYHA class > I). The overall median NT-proBNP was 268.92 pmol/L (interquartile range [IQR]: 89.94 to 828.70 pmol/L). Among various VHD, the highest NT-proBNP levels were detected in patients with multivalvular heart disease (379.96 pmol/L [IQR: 146.07 to 1188.53 pmol/L]) and mitral regurgitation (294.88 pmol/L [IQR: 98.44 to 917.75 pmol/L), and the lowest levels were observed in patients with aortic regurgitation (112.04 pmol/L [IQR: 31.92 to 408.04 pmol/L). NT-pro BNP levels correlated with age (r=0.131, p<0.0001). Noteworthily, no significant difference was found between men and women. In general, NT-proBNP correlated with left ventricular ejection fraction (LVEF, r=−0.438, p<0.001), left ventricular end-diastolic dimension (LVEDD, r=0.16, p<0.001) and left atrial dimension (LA, r=0.081, p<0.001). All those correlations were stronger in aortic valve disease than mitral valve disease. Diagnostic ability of NT-proBNP to differentiate severe VHD was limited and varied among different VHD (AUC: 0.62 [0.54, 0.69] in AS, 0.61 [0.53, 0.69] in MS, 0.58 [0.53, 0.63] in AR, 0.49 [0.47, 0.53] in MR). Spline curves revealed a strong association between NT-proBNP and mortality. In the overall population, after adjustment of propensity score accounting for age, sex, coronary heart disease, diabetes, cardiomyopathy, symptoms, severity, LVEF, and valvular intervention, NT-proBNP was a powerful, independent, and incremental predictor of mortality (log transformation, HR: 1.38; [95% CI: 1.30 to 1.46], p<0.001). Moreover, we dichotomized NT-proBNP in severe and nonsevere using median values in various VHD. Except for MS, other VHDs all incurred excess mortality with severe NT-proBNP, especially in aortic stenosis (HR: 17.21; [95% CI: 4.08 to 72.60], p<0.001) and aortic regurgitation (HR: 5.10; [95% CI: 2.13 to 12.22], p<0.001). Conclusion Levels of NT-proBNP significantly differ by diagnosis in VHD patients and correlate with echocardiographic parameters to varying degrees, reflecting different hemodynamic changes. In patients with VHD other than single mitral stenosis, NT-proBNP is a powerful, independent, and incremental predictor of mortality. Thus, measurement of NT-proBNP should be considered in the VHD population for further risk stratification. Acknowledgement/Funding Key Projects in the National Science & Technology Pillar Program during the 12th five-year Plan

Determinants of N-terminal ProBNP Levels in Patients with Atrial Fibrillation and Preserved Left Ventricular Systolic Function

Determinants of N-terminal proBNP Levels in Ustable Angina Patients with Preserved Left Ventricular Function

Effect of atrial fibrillation on plasma NT-proBNP in patients with different cardiac functions PAN

Corelation Between Plasma N-terminal ProBNP(NT-proBNP) and Cardiac Dysfunction

Influence of Atrial Fibrillation Type on Plasma Brain Natriuretic Peptide Level in Male Patients

Predictive value of NT pro BNP for new‐onset atrial fibrillation in heart failure and preserved ejection fraction

Effect of Bradyarrhythmia on the Plasma Levels of N-terminal Pro-Brain Natriuretic Peptide

Value Of Serum Nt-Probing Elevation In Predicting Risk Of Atrial Fibrillation In Elderly Male Patients With Normal Heart Function

Influencing factors for plasma natriuretic peptide and N-terminal pro-B-type natriuretic peptide levels in senior patients with heart failure

Forecasting Atrial Fibrillation: The Predictive Power of N-terminal Prohormone of Brain Natriuretic Peptide in a Five-Year Study

The role of amino-terminal pro-B-type natriuretic peptide for evaluating the risk stratification in patients with chronic heart failure and low left ventricular ejection fraction

NT-proBNP predicts new-onset atrial fibrillation following acute myocardial infarction

Longitudinal NT-proBNP: Associations With Echocardiographic Changes and Outcomes in Heart Failure

The association of NT-proBNP levels in atrial fibrillation patients and 3-year risk of heart hospitalization and death

Relationship between the serum N-terminal pro B-type natriuretic peptide levels and left ventricular function in patients with cardiovascular disease

NTproBNP values for diagnosis of congestive heart failure in old patients regarding atrial fibrillation

Clinical characteristics and outcomes of patients hospitalized with heart failure with preserved ejection fraction and low NT-proBNP levels

Prognostic value of N-terminal B-type natriuretic peptide in patients with chronic heart failure

P4664N-terminal pro-B-type natriuretic peptide and its relationship with cardiac function and prognosis in elderly patients with valvular heart disease

Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction

Early predictive values of NT-proBNP for acute myocardial ischemia related heart failure with preserved ejection fraction